Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Non-Current Assets (2022 - 2025)

Historic Non-Current Assets for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $7.0 million.

  • Orchestra BioMed Holdings' Non-Current Assets rose 403.49% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 1268.58%. This contributed to the annual value of $7.0 million for FY2024, which is 1482.45% up from last year.
  • Per Orchestra BioMed Holdings' latest filing, its Non-Current Assets stood at $7.0 million for Q3 2025, which was up 403.49% from $6.9 million recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' Non-Current Assets ranged from a high of $160.2 million in Q2 2022 and a low of $5.9 million during Q2 2024
  • Over the past 4 years, Orchestra BioMed Holdings' median Non-Current Assets value was $6.9 million (recorded in 2025), while the average stood at $31.4 million.
  • Per our database at Business Quant, Orchestra BioMed Holdings' Non-Current Assets crashed by 9607.28% in 2023 and then surged by 1763.81% in 2025.
  • Orchestra BioMed Holdings' Non-Current Assets (Quarter) stood at $10.9 million in 2022, then plummeted by 43.96% to $6.1 million in 2023, then rose by 14.82% to $7.0 million in 2024, then rose by 0.53% to $7.0 million in 2025.
  • Its last three reported values are $7.0 million in Q3 2025, $6.9 million for Q2 2025, and $7.1 million during Q1 2025.